IHH:MYXIHH Healthcare Bhd. Analysis
Data as of 2026-03-11 - not real-time
$1.45
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
IHH Healthcare trades at $1.45 with an RSI of 100, signaling extreme overbought conditions, while the MACD histogram is negative and the signal line is bearish, suggesting short‑term downside pressure. Valuation metrics are attractive – a trailing PE of 20.7 versus the industry average of 25.2, a price‑to‑book of 1.68, and a DCF‑derived fair value of roughly $3.11, indicating the stock may be significantly undervalued.
Fundamentally, the company posts a modest profit margin of 8.2%, a dividend yield of 1.64% with a 40% payout ratio, and solid operating cash flow despite a slight free‑cash‑flow deficit. Recent news adds a mixed tone: a major Turkish shareholder trimmed its stake, while IHH announced an oncology expansion through an investment in US firm TibaRay, providing a potential growth catalyst.
Fundamentally, the company posts a modest profit margin of 8.2%, a dividend yield of 1.64% with a 40% payout ratio, and solid operating cash flow despite a slight free‑cash‑flow deficit. Recent news adds a mixed tone: a major Turkish shareholder trimmed its stake, while IHH announced an oncology expansion through an investment in US firm TibaRay, providing a potential growth catalyst.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- RSI at 100 indicating overbought conditions
- Bearish MACD signal and negative histogram
- Stake reduction by a major Turkish shareholder
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervaluation relative to DCF and peer PE
- Oncology expansion via TibaRay investment
- Attractive dividend yield with sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Diversified geographic footprint reducing single‑market exposure
- Long‑term secular growth in healthcare demand
- Consistent cash generation supporting dividend and debt service
Key Metrics & Analysis
Financial Health
Revenue Growth-1.60%
Profit Margin8.16%
P/E Ratio20.7
ROE7.67%
ROA4.12%
Debt/Equity45.59
P/B Ratio1.7
Op. Cash Flow$5.6B
Free Cash Flow$-65875000
Industry P/E25.2
Technical Analysis
TrendNeutral
RSI100.0
Support$1.45
Resistance$1.45
MA 20$1.45
MA 50$1.45
MA 200$1.31
MACDBearish
VolumeStable
Fear & Greed Index76.46
Valuation
Fair Value$3.11
GradeUndervalued
TypeBlend
Dividend Yield1.64%
Risk Assessment
Beta-0.07
0Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.